Featured News
Press Release
Strong Bipartisan Support for Continued Investment in Alzheimer’s Research on Full Display During Senate Appropriations Hearing
Senate appropriators from both sides of the aisle raise warnings of harm that would come from proposed research funding and staff cuts Washington, D.C., April 30, 2025 — During today’s Senate Appro...
All News
AIM Blog
Alzheimer’s Advocates Rally for CMS to “Fix This Mess” and Stop Blocking Access to Alzheimer’s Treatments
In communities across the nation, passionate Alzheimer’s advocates put on their purple, picked up their signs and rallied for access...
Press Release
Alzheimer’s Association, Individuals Living with Alzheimer’s Urge FDA to Grant Traditional Approval for Lecanemab
CHICAGO, May 25, 2023 — The Alzheimer's Association and members of the Association's Early Stage Advisory Group submitted comments to...
Press Release
Alzheimer’s Advocate Testifies What Access to FDA-Approved Alzheimer’s Treatments Means
— Congressional Bipartisan Support for Individuals, Families and Treatment on Display — WASHINGTON, D.C., May 10, 2023 — Today, Tony...
Press Release
Alzheimer’s Association Statement on Donanemab Phase 3 Topline Data Release
Strongest Alzheimer's Phase 3 data release to date Association underscores urgent call for CMS to stop blocking access to FDA-approved...
AIM Blog
Recognizing AIM’s May Advocate of the Month: Priya Patel
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
Press Release
Overwhelming Bipartisan Support for Access to FDA-Approved Alzheimer’s Treatments on Display in Health Subcommittee Hearing
Bipartisan members sharply question CMS Administrator why Alzheimer’s drugs aren’t reasonable and necessary Washington, D.C., April 26, 2023 — Today...